Lyra Therapeutics Inc Market Cap ($337.23K)
Market Cap & Net Worth: Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics Inc market cap. Lyra Therapeutics Inc (NASDAQ:LYRA) has a market capitalization of $337.23K ($337.23K) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31212 globally and #6335 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyra Therapeutics Inc's stock price $0.20 by its total outstanding shares 1774882 (1.77 Million).
Lyra Therapeutics Inc Market Cap History (2020–2026)
Lyra Therapeutics Inc market cap history from 2020 to 2026. Data shows change from $20.23 Million to $354.98K (-50.91% CAGR). Check Lyra Therapeutics Inc stock quote for real-time trading data and today's change.
Index Memberships
Lyra Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #918 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2893 of 3165 |
Weight: Lyra Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lyra Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyra Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does Lyra Therapeutics Inc generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
13.74x
Lyra Therapeutics Inc's market cap is 13.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $7.74 Million | $285.00K | -$42.41 Million | 27.15x | N/A |
| 2022 | $5.57 Million | $1.36 Million | -$55.28 Million | 4.09x | N/A |
| 2023 | $9.30 Million | $1.56 Million | -$62.68 Million | 5.97x | N/A |
| 2024 | $366.34K | $1.53 Million | -$93.44 Million | 0.24x | N/A |
| 2025 | $5.47 Million | $398.00K | -$28.92 Million | 13.74x | N/A |
Competitor Companies of LYRA by Market Capitalization
Companies near Lyra Therapeutics Inc in the global market cap rankings as of October 31, 2026. See how leveraged is Lyra Therapeutics Inc's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Lyra Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Lyra Therapeutics Inc (2020–2026)
Market capitalization of Lyra Therapeutics Inc from 2020 to today. Between 2020 and today, Lyra Therapeutics Inc's market cap moved from $20.23 Million to $ 354.98K, with a yearly change of -50.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $354.98K | -93.51% |
| 2025 | $5.47 Million | +1392.25% |
| 2024 | $366.34K | -96.06% |
| 2023 | $9.30 Million | +66.88% |
| 2022 | $5.57 Million | -27.98% |
| 2021 | $7.74 Million | -61.75% |
| 2020 | $20.23 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Lyra Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $337.23K USD |
| MoneyControl | $337.23K USD |
| MarketWatch | $337.23K USD |
| marketcap.company | $337.23K USD |
| Reuters | $337.23K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more